Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 239

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 239
---
ed microRNAs as biomarkers
of Rett Syndrome.”

The accompanying consolidated financial statements
have been prepared assuming that DiamiR will continue as a going concern, which contemplates, among other things, the realization of assets
and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments
that might be necessary if DiamiR is unable to continue as a going concern.

Recent Events

In May 2025, DiamiR entered into a fee-for-service
agreement to perform exploratory blood biomarker testing for a life sciences company developing therapeutic agent for AD.

In May 2025, DiamiR was successfully renewed its
CT State and CLIA licenses after an inspection of its New Haven CT laboratory by State inspectors.

In April 2025, DiamiR launched its microRNA testing
services and updated its website to advertise this service to prospective biopharma customers.

<div align='center'>122</div>

In April 2025, DiamiR successfully passed its
CAP inspection and was granted a 2-year extension on its CAP accreditation until 2027.

In April 2025 and June 2025, DiamiR amended the convertible note with
Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned DiamiR additional $100,000 or $150,000,
respectively.

Financial Operations Overview

Revenue

In 2010, DiamiR began the process of developing CogniMIR.
To date, DiamiR has primarily earned revenue from grants and have not generated any product revenue other than revenues from research
testing services for third parties and other revenue generated for performing laboratory services DiamiR previously provided to Interpace
Biosciences, Inc. (“Interpace”). DiamiR’s ability to generate product revenue, which it does not expect to occur until
at least second half 2025, if ever, will depend heavily on DiamiR’s ability to comply with regulatory requirements for, and to commercialize
successfully, CogniMIR and other tests in development.

Total Operating Expense

Total operating costs and
expenses consisted primarily of analyzing samples and clinical data associated with revenues from research testing services performed,
patent costs and general and administrative costs.

Results of Operations

Nine Months Ended February 28, 2025 and February 29, 2024

The following table sets forth certain information
concerning DiamiR’s results of operations